The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Tran M.D.

Pirogov Russian National Research Medical University

Yasamanova A.N.

Pirogov Russian National Research Medical University

Avakyan G.G.

Pirogov Russian National Research Medical University

Nikonova A.A.

Pirogov Russian National Research Medical University

Kamchatnov P.R.

Pirogov Russian National Research Medical University

The multidirectional effects of thrombin and the possibility of their control in neurology

Authors:

Tran M.D., Yasamanova A.N., Avakyan G.G., Nikonova A.A., Kamchatnov P.R.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3‑2): 42‑48

DOI: 10.17116/jnevro202412403242

Read: 1834 times

Download PDF (RU)
Contact the author
Table of contents

THE MULTIDIRECTIONAL EFFECTS OF THROMBIN AND THE POSSIBILITY OF THEIR CONTROL IN NEUROLOGY
THE MULTIDIRECTIONAL EFFECTS OF THROMBIN AND THE POSSIBILITY OF THEIR CONTROL IN NEUROLOGY

To cite this article:

Tran MD, Yasamanova AN, Avakyan GG, Nikonova AA, Kamchatnov PR. The multidirectional effects of thrombin and the possibility of their control in neurology. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;124(3‑2):42‑48. (In Russ.)
https://doi.org/10.17116/jnevro202412403242

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски (S.S. Korsakov Journal of Neurology and Psychiatry (special issues))
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Early anti­thrombotic protection of the brain in patients with ischemic stroke. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):5-10
Adju­vant pharmacological modu­lation with Cyto­flavin in reha­bilitation at stages 2—3 in patients with acute cere­bral insu­fficiency and post-intensive care syndrome. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):78-85
Anesthetic mana­gement of endo­vascular procedures in patients with ischemic stroke. Russian Journal of Anesthesiology and Reanimatology. 2025;(2):20-25
Comparison of fluoroscopy and intracardiac echo­cardiography for control of endo­vascular closure of patent fora­men ovale. Russian Cardiology Bulletin. 2025;(1):64-69
Mathematical mode­ling of outcomes in patients with clinical combination of ischemic stroke and COVID-19 complicated by multiple organ failure. Russian Journal of Anesthesiology and Reanimatology. 2025;(3):42-49
Socio-economic damage caused by elevated low-density lipo­protein cholesterol levels. Medi­cal Technologies. Asse­ssment and Choice. 2025;(2):88-98
Hemo­stasis diso­rders during neoadjuvant therapy in patients with breast cancer. P.A. Herzen Journal of Onco­logy. 2025;(3):39-44
Cere­brolysin with repe­rfusion therapy in ischemic stroke: a prospective analysis of multimodal brain imaging data from the CERE­HETIS trial. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):84-98
Prediction of mortality in severe ischemic stroke during COVID-19 in patients with multiorgan dysfunction. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(6):120-127
A clinical case of treating a patient with severe ischemic stroke and cancer. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8):114-117
Abstract:

The review presents the main physiological functions of thrombin. The procoagulant and anticoagulant activities of the key serine protease are discussed in both physiological and pathological conditions of hemostasis. The involvement of thrombin in atherogenesis, as well as its role as a mediator of vascular dysfunction and inflammation in both the peripheral and central nervous system, is highlighted. A pronounced imbalance between the pro- and anticoagulant systems leads to an increase in thrombin formation and creates conditions for the development of thrombosis. Tests that allow direct or indirect assessment of thrombin’s functional activity are presented. The potential applications of direct thrombin inhibitors and direct blockers of thrombin PAR receptors in vascular neurology are also considered.

Keywords:

thrombin
ischemic stroke
hemostasis
platelets
anticoagulant
direct thrombin inhibitors
vorapaxar

Authors:

Tran M.D.

Pirogov Russian National Research Medical University

Yasamanova A.N.

Pirogov Russian National Research Medical University

Avakyan G.G.

Pirogov Russian National Research Medical University

Nikonova A.A.

Pirogov Russian National Research Medical University

Kamchatnov P.R.

Pirogov Russian National Research Medical University

Received:

20.12.2023

Accepted:

29.12.2023

Close metadata

References:

  1. Sturov VG, Sergeeva IG, Tulupov AA. Cerebrovascular diseases and pathology of hemostasis: textbook; Novosib. state univ. Novosibirsk: RIC NSU; 2015. (In Russ.).
  2. Borissoff JI, Spronk HM, Heeneman S, et al. Is thrombin a key player in the «coagulation-atherogenesis» maze? Cardiovasc Res. 2009;82(3):392-403.  https://doi.org/10.1093/cvr/cvp066
  3. Wu J, Heemskerk JWM, Baaten CCFMJ. Platelet Membrane Receptor Proteolysis: Implications for Platelet Function. Front Cardiovasc Med. 2021;7:608391. https://doi.org/10.3389/fcvm.2020.608391
  4. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost. 2013;11(1):2-16.  https://doi.org/10.1111/jth.12045
  5. Al-Amer OM. The role of thrombin in haemostasis. Blood Coagul Fibrinolysis. 2022;33(3):145-148.  https://doi.org/10.1097/MBC.0000000000001130
  6. Jackson SP, Darbousset R, Schoenwaelder SM. Thromboinflammation: challenges of therapeutically targeting coagulation and other host defense mechanisms. Blood. 2019;133(9):906-918.  https://doi.org/10.1182/blood-2018-11-882993
  7. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for the activation of factor XI by thrombin. Blood. 2011;118(26):6963-6970. https://doi.org/10.1182/blood-2011-07-368811
  8. Galstyan GM, Klebanova EE. Diagnosis of thrombotic thrombocytopenic purpura. Terapevticheskii Arkhiv. 2020;92(12):207-217. (In Russ.). https://doi.org/10.26442/00403660.2020.12.200508
  9. Leebeek FW, Goor MP, Guimaraes AH, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost. 2005;3(10):2211-2218. https://doi.org/10.1111/j.1538-7836.2005.01484.x
  10. Furie B, Furie BC. In vivo thrombus formation. J Thromb Haemost. 2007;5(suppl 1):12-17.  https://doi.org/10.1111/j.1538-7836.2007.02482.x
  11. Huntington JA. Natural inhibitors of thrombin. Thromb Haemost. 2014;111(4):583-589.  https://doi.org/10.1160/TH13-10-0811
  12. Kasthuri RS, Glover SL, Boles J, et al. Tissue factor and tissue factor pathway inhibitor as key regulators of global hemostasis: measurement of their levels in coagulation assays. Semin Thromb Hemost. 2010;36(7):764-771.  https://doi.org/10.1055/s-0030-1265293
  13. Langdown J, Johnson DJ, Baglin TP. Et al. Allosteric activation of antithrombin critically depends upon hinge region extension. J Biol Chem. 2004;279(45):47288-47297. https://doi.org/10.1074/jbc.M408961200
  14. Mosnier LO, Griffin JH. Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities. Front Biosci. 2006;11:2381-2399. https://doi.org/10.2741/1977
  15. Li W, Adams TE, Nangalia J, et al. Molecular basis of thrombin recognition by protein C inhibitor revealed by the 1.6-A structure of the heparin-bridged complex. Proc Natl Acad Sci U S A. 2008;105(12):4661-4666. https://doi.org/10.1073/pnas.0711055105
  16. Mutch NJ. Regulation of Fibrinolysis by Platelets. In: Michelson AD, eds. Platelets (Fourth Edition). Academic Press; 2019;417-431.  https://doi.org/10.1016/B978-0-12-813456-6.00023-0
  17. Wang Z, Castresana MR, Newman WH. Reactive oxygen species-sensitive p38 MAPK controls thrombin-induced migration of vascular smooth muscle cells. J Mol Cell Cardiol. 2004;36(1):49-56.  https://doi.org/10.1016/j.yjmcc.2003.09.014
  18. Kaplan ZS, Zarpellon A, Alwis I, et al. Thrombin-dependent intravascular leukocyte trafficking regulated by fibrin and the platelet receptors GPIb and PAR4. Nat Commun. 2015;6:7835. https://doi.org/10.1038/ncomms8835
  19. Burzynski LC, Humphry M, Pyrillou K, et al. The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1α by Thrombin. Immunity. 2019;50(4):1033-1042.e6.  https://doi.org/10.1016/j.immuni.2019.03.003
  20. Jaberi N, Soleimani A, Pashirzad M, et al. Role of thrombin in the pathogenesis of atherosclerosis. J Cell Biochem. 2019;120(4):4757-4765. https://doi.org/10.1002/jcb.27771
  21. Fang X, Liao R, Yu Y, et al. Thrombin Induces Secretion of Multiple Cytokines and Expression of Protease-Activated Receptors in Mouse Mast Cell Line. Mediators Inflamm. 2019;2019:4952131. https://doi.org/10.1155/2019/4952131
  22. Petzold T, Massberg S. Thrombin: A Gas Pedal Driving Innate Immunity. Immunity. 2019;50(4):1024-1026. https://doi.org/10.1016/j.immuni.2019.03.006
  23. Iannucci J, Renehan W, Grammas P. Thrombin, a Mediator of Coagulation, Inflammation, and Neurotoxicity at the Neurovascular Interface: Implications for Alzheimer’s Disease. Front Neurosci. 2020;14:762.  https://doi.org/10.3389/fnins.2020.00762
  24. Siller-Matula JM, Schwameis M, Blann A, et al. Thrombin as a multi-functional enzyme. Focus on in vitro and in vivo effects. Thromb Haemost. 2011;106(6):1020-1033. https://doi.org/10.1160/TH10-11-0711
  25. Dobrovolsky AB, Titaeva EV. Thrombin formation and its functions in the hemostasis system. Aterotromboz. 2013;(1):66-72. (In Russ.). https://doi.org/10.21518/2307-1109-2013-1-66-72
  26. Abramov EA, Ivanova AE, Dashinimaev EB, et al. Effect of thrombin on cultured rat astrocytes subjected to oxygen-glucose deprivation. Biological Membranes: Journal of Membrane and Cell Biology. 2022;39(1):18-27. (In Russ.). https://doi.org/10.31857/S0233475522010042
  27. Hemker HC, Giesen P, Al Dieri R, et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003;33(1):4-15.  https://doi.org/10.1159/000071636
  28. Dukhin OA, Kalinsaya AI, Shpektor AV, et al. The role of thrombin in the pathogenesis of atherosclerosis and its complications. Kardiologiia. 2022;62(3):73-81. (In Russ.). https://doi.org/10.18087/cardio.2022.3.n1968
  29. Lee CJ, Ansell JE. Direct thrombin inhibitors. Br J Clin Pharmacol. 2011;72(4):581-592.  https://doi.org/10.1111/j.1365-2125.2011.03916.x
  30. Diener HC. Pro: «The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation.». Thromb Haemost. 2013;110(3):493-495.  https://doi.org/10.1160/TH13-04-0277
  31. Heidbuchel H, Verhamme P, Alings M, et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J. 2013;34(27):2094-2106. https://doi.org/10.1093/eurheartj/eht134
  32. Seiffge DJ, Werring DJ, Paciaroni M, et al. Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol. 2019;18(1):117-126.  https://doi.org/10.1016/S1474-4422(18)30356-9
  33. Tkacheva ON, Akasheva DU. Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice. Terapevticheskii Arkhiv. 2014;86(4):103-107. (In Russ.).
  34. Schulman S, Kearon C, Kakkar AK, et al.; RE-MEDY Trial Investigators; RE-SONATE Trial Investigators. Extended use of dabigatran, warfarin, or placebo in venous thromboembolism. N Engl J Med. 2013;368(8):709-718.  https://doi.org/10.1056/NEJMoa1113697
  35. Blech S, Ebner T, Ludwig-Schwellinger E, et al. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-399.  https://doi.org/10.1124/dmd.107.019083.
  36. Furugohri T, Sugiyama N, Morishima Y, et al. Antithrombin-independent thrombin inhibitors, but not direct factor Xa inhibitors, enhance thrombin generation in plasma through inhibition of thrombin-thrombomodulin-protein C system. Thromb Haemost. 2011;106(6):1076-1083. https://doi.org/10.1160/TH11-06-0382
  37. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. European Heart Journal. 2020;42(5):373-498.  https://doi.org/10.1093/eurheartj/ehaa612
  38. Diener HC, Sacco RL, Easton JD, et al.; RE-SPECT ESUS Steering Committee and Investigators. Dabigatran for Prevention of Stroke after Embolic Stroke of Undetermined Source. N Engl J Med. 2019;380(20):1906-1917. https://doi.org/10.1056/NEJMoa1813959
  39. Toyoda K, Uchiyama S, Hagihara Y, et al. Dabigatran vs. Aspirin for Secondary Prevention After Embolic Stroke of Undetermined Source — Japanese Subanalysis of the RE-SPECT ESUS Randomized Controlled Trial. Circ J. 2020;84(12):2286-2295. https://doi.org/10.1253/circj.CJ-20-0563
  40. Butcher KS, Ng K, Sheridan P, et al. Dabigatran Treatment of Acute Noncardioembolic Ischemic Stroke. Stroke. 2020;51(4):1190-1198. https://doi.org/10.1161/STROKEAHA.119.027569
  41. Pollack CV Jr, Reilly PA, Eikelboom J, et al. Idarucizumab for Dabigatran Reversal. N Engl J Med. 2015;373(6):511-520.  https://doi.org/10.1056/NEJMoa1502000
  42. Ushkalova E.A. Vorapaxar is the first representative of a new class of antiplatelet agents. Pharmateka. 2014;9(282):76-80. (In Russ.).
  43. U.S. Food and Drug Administration. Drug Trials Snapshot: Zontivity (vorapaxar) [press release]. September 5, 2017. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshot-zontivity-vorapaxar
  44. Morrow DA, Braunwald E, Bonaca MP, et al. TRA 2P—TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012;366(15):1404-1413. https://doi.org/10.1056/NEJMoa1200933
  45. Serebruany VL, Kim MH, Hanley DF. Vorapaxar monotherapy for secondary stroke prevention: A call for randomized trial. Int J Stroke. 2016;11(6):614-617.  https://doi.org/10.1177/1747493016632253
  46. Kolodzeyskaya MV, Grishchuk VI, Chernyshenko TM, et al. Recombinant anticoagulant form of human α-thrombin. Biotechnol acta. 2009;3:12-19. (In Russ.).
  47. Receivd 20.12.2023 
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.